Literature DB >> 19045943

Enhancing brain adenosine signaling with the nucleoside transport blocker NBTI (S-(4-nitrobenzyl)-6-theoinosine) mimics the effects of inescapable shock on later shuttle-escape performance in rats.

Thomas R Minor1, Michael Rowe, Patrick K Cullen, Stephanie Furst.   

Abstract

Experience with unsignaled, inescapable shock represents a profound challenge to brain metabolic function and physiology. The authors have argued that behavioral impairment following this traumatic stress is a consequence of enhanced brain adenosine signaling, which promotes metabolic recovery by profoundly inhibiting neural activation. The authors tested this hypothesis by artificially increasing extracellular brain adenosine concentration by blocking uptake transport with NBTI in rats given only restraint stress in five experiments. NBTI impaired shuttle-escape performance in the manner of inescapable shock in a dose-dependent manner and acted synergistically with an ineffective number of inescapable shocks to maximally impair test performance. These deficits produced by inescapable shock and NBTI were reversed by the nonselective adenosine receptor antagonist caffeine, and the highly selective A-sub(2A) receptor antagonist CSC (8-(3-chloro-styrl)caffeine). The highly selective A-sub-1 receptor antagonist DPCPX (8-Cyclopentyl-1,3-Dipropylxanthine) failed to improve performance in rats preexposed to inescapable shock or pretreated with NBTI. These data suggest that enhanced adenosine signaling at a brain A-sub(2A) receptor impairs escape performance following inescapable shock in the learned helplessness paradigm.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19045943     DOI: 10.1037/a0013143

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  7 in total

1.  Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats.

Authors:  Koji Yamada; Minoru Kobayashi; Shizuo Shiozaki; Teruko Ohta; Akihisa Mori; Peter Jenner; Tomoyuki Kanda
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

2.  Caffeine acts through neuronal adenosine A2A receptors to prevent mood and memory dysfunction triggered by chronic stress.

Authors:  Manuella P Kaster; Nuno J Machado; Henrique B Silva; Ana Nunes; Ana Paula Ardais; Magda Santana; Younis Baqi; Christa E Müller; Ana Lúcia S Rodrigues; Lisiane O Porciúncula; Jiang Fan Chen; Ângelo R Tomé; Paula Agostinho; Paula M Canas; Rodrigo A Cunha
Journal:  Proc Natl Acad Sci U S A       Date:  2015-06-08       Impact factor: 11.205

3.  Signaling pathways underlying the antidepressant-like effect of inosine in mice.

Authors:  Filipe Marques Gonçalves; Vivian Binder Neis; Débora Kurrle Rieger; Mark William Lopes; Isabella A Heinrich; Ana Paula Costa; Ana Lúcia S Rodrigues; Manuella P Kaster; Rodrigo Bainy Leal
Journal:  Purinergic Signal       Date:  2016-12-13       Impact factor: 3.765

4.  Nitrobenzylthioinosine mimics adenosine to attenuate the epileptiform discharge of hippocampal neurons from epileptic rats.

Authors:  Hao Huang; Jing Wang; Jun Zhang; Zhong Luo; Dongxu Li; Xiaowei Qiu; Yan Peng; Zhongxiang Xu; Ping Xu; Zucai Xu
Journal:  Oncotarget       Date:  2017-05-30

Review 5.  Caffeine and Selective Adenosine Receptor Antagonists as New Therapeutic Tools for the Motivational Symptoms of Depression.

Authors:  Laura López-Cruz; John D Salamone; Mercè Correa
Journal:  Front Pharmacol       Date:  2018-06-01       Impact factor: 5.810

6.  Post-stress glucose consumption facilitates hormesis and resilience to severe stress.

Authors:  Traci N Plumb; Michael A Conoscenti; Thomas R Minor; Michael S Fanselow
Journal:  Stress       Date:  2021-06-11       Impact factor: 3.493

7.  Inhibition of p38 MAPK regulates epileptic severity by decreasing expression levels of A1R and ENT1.

Authors:  Xuejiao Zhou; Qian Chen; Hao Huang; Jun Zhang; Jing Wang; Ya Chen; Yan Peng; Haiqing Zhang; Junwei Zeng; Zhanhui Feng; Zucai Xu
Journal:  Mol Med Rep       Date:  2020-10-19       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.